Amariati, Heldah

Betti, Peter

Gondi, Stacey

Hooker, Juzar

Hussein, Yuashita

Karimi, Noureen

Saleh, Mansoor

Shamshudin, Aisleen

Sokhi, Dilraj

Williams, Mitzi J.

English

eCommons@AKU

eCommons@AKU Book Chapters / Conference Papers 10-2022 Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial Dilraj Sokhi Juzar Hooker Mitzi J. Williams Aisleen Shamshudin Yuashita Hussein See next page for additional authors Follow this and additional works at: https://ecommons.aku.edu/book_chapters  Part of the Neurology Commons Authors Dilraj Sokhi, Juzar Hooker, Mitzi J. Williams, Aisleen Shamshudin, Yuashita Hussein, Peter Betti, Heldah Amariati, Noureen Karimi, Stacey Gondi, and Mansoor Saleh BACKGROUNDScan Quick Response (QR) code or click link  to download a pdf and enhanced content.  Copies of this poster obtained through QR  code are for personal use only and may not  be reproduced without permission from  ECTRIMS and the author of this poster.REFERENCES1. Yamout BI, et al. Mult Scler J Exp Transl Clin 2020;6:2055217319841881.2. Hauser SL, et al. N Engl J Med 2017;376:221–234.3. Montalban X, et al. N Engl J Med 2017;376:209–220.4. Ocrevus. Prescribing information. Genentech, Inc; 2021.DISCLOSURES D.S. Sokhi has received speaker fees from F. Hoffmann-La Roche Ltd. J. Hooker has nothing to disclose. M.J. Williams has received honoraria for speaking, consulting  or serving on steering committees for AbbVie, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Inc., Janssen, Novartis, TG Therapeutics and Sanofi Genzyme.  L. Amezcua reports personal compensation for consulting, speaking or serving on steering committees or advisory boards for Biogen Idec, Novartis, Alexion Pharmaceuticals, Genentech, Inc., EMD Serono and AbbVie and research support from the National Multiple Sclerosis Society, National Institutes of Health National Institute of Neurological Disorders and Stroke and Biogen. A. Shamsudin, Y.E. Hussein, P. Betti, H. Amariati, N. Karimi and S. Gondi have nothing to disclose. J. Pei is an employee of  Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd. H. Bulhan and D. Okaka are employees of F. Hoffman La Roche Ltd, Nairobi, Kenya. J. Acosta is an  employee of Genentech, Inc., and a shareholder of F. Hoffmann-La Roche Ltd. M. Saleh has nothing to disclose. Presented at 2022 ECTRIMS 26–28 October 2022; Amsterdam, the Netherlands.Demographics and Baseline Disease Characteristics  of Patients With Relapsing Multiple Sclerosis From Kenya  Participating in the CHIMES TrialDilraj Singh Sokhi,1 Juzar Hooker,1 Mitzi J. Williams,2 Lilyana Amezcua,3 Aisleen Shamshudin,1 Yuashita Evochi Hussein,1 Peter Betti,1 Heldah Amariati,1 Noureen Karimi,1 Stacey Gondi,1 Jinglan Pei,4 Huwaida Bulhan,5 Dennis Okaka,6 Juan Acosta,4 and Mansoor Saleh11Aga Khan University, Nairobi, Kenya; 2Joi Life Wellness Center, Atlanta, GA, USA; 3Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;  4Genentech, Inc., South San Francisco, CA, USA; 5F. Hoffmann-La Roche Ltd, Basel, Switzerland; 6F. Hoffmann-La Roche Ltd, Singapore There is a paucity of epidemiological studies on multiple sclerosis (MS) in Black people from Africa, and this ethnic population is historically underrepresented in MS1The CHIMES trial (NCT04377555) is an ongoing, open-label, single-arm, Phase IV clinical study that is investi-gating the efficacy and safety of ocrelizumab (OCR) in Black and Hispanic patients with relapsing MS (RMS)Self-identified Black and Hispanic patients aged 18 to 65 years with RMS and an Expanded Disability Status Scale (EDSS) score of ≤5.5 were recruited at all study sitesOCR, currently approved in North America for RMS and primary progressive MS and pending government approval in Kenya, is a humanised monoclonal antibody that selectively targets CD20+ B cells and reduces the rates of disease activity and progression2,3,4EP1049The CHIMES trial is a North American trial with one site in KenyaTo promote inclusive recruitment in Kenya:North AmericaUnited StatesPuerto RicoAfricaKenya• Study-related patient materials were  available in English and Kiswahili• Flexible scheduling options were  based on specific needs of the  catchment area to also recruit from  rural areas and comply with local  healthcare ecosystemsKEY FINDINGSCONCLUSIONSBaseline Patient Demographicsa 94.5%5.5%North America KenyaOf 182 enrolled patients, 10 are in Kenya and all self-identify as Black0102030405060708090100Age, year Female, % Body weight, kgMean, (SD)37.8 (9.6)35.5(10.5)70 7269.7(13.5)86.8 (22.2)Kenyan patients (n=10)All patients(N=182)Kenyan patients were observed to have a lower mean body weight than the total population Baseline Disease Demographicsa 00.511.522.533.54"Mean, (SD)051015202530!Kenyan patients (n=10)All patients(N=182)Time since RMS diagnosis, year EDSS score No. of relapses in past 24 monthsNo. of Gd-enhancingT1 lesionsVolume of T2 lesions, cm31.5(1.9)2.9(4.5)3.5(1.9)2.4(1.4)1.2 (0.4) 0.7(0.6)2.2(3.7) 1.9(4.3)27.4(21.3)18.9(18.1)• Kenyan patients were observed  to have a shorter time since  diagnosis and higher disease  disability and burden than the  total population• Mean time since first MS  symptoms, time since onset  of last MS relapse before  enrolment and normalised brain  and thalamic volume were  observed to be similar between  both groupsaNo statistical comparisons were made due to the small sample size.Gd, gadolinium. aNo statistical comparisons were made due to the small sample size.•  CHIMES is the first Phase IV clinical trial to prospectively assess patients with RMS from sub-Saharan Africa•  Differences observed in demographic and disease characteristics between patients with RMS enrolled in the  Kenyan and North American sites highlight the importance of enrolling more diverse populations in RMS trials  and conducting more demographic-specific studiesSponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Editorial assistance was provided by Health Interactions, Inc., USA, and funded by F. Hoffmann-La Roche Ltd , Basel, Switzerland.https://bit.ly/3DUYdqs

Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial

https://ecommons.aku.edu/cgi/viewcontent.cgi?article=1487&context=book_chapters

Demographics and baseline disease characteristics of patients with relapsing multiple sclerosis from Kenya participating in the CHIMES trial

Abstract

Similar works

Full text

Available Versions

eCommons@AKU